Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.
Vericel Corporation filed a Form 144 reporting an affiliate sale of common stock; the filing lists a 03/02/2026 proposed sale tied to an option exercise of 15,000 shares through Fidelity Brokerage Services LLC. The filing also lists recent restricted stock vesting entries of 1,510, 1,295, 1,947, and 1,669 shares on 02/17/2026, 02/18/2026, 02/20/2026, and 02/22/2026, respectively.
VCEL submitted a Form 144 reporting planned sales of common stock held at Fidelity Brokerage Services LLC. The notice lists multiple restricted stock vesting entries: 2,764 shares on
The filing identifies the broker as Fidelity Brokerage Services LLC and indicates Nasdaq as the market; additional transactional details are not included in the excerpt.
Vericel Corp President and CEO Dominick Colangelo reported equity award vesting and related share movements. On
Vericel Corp Chief Medical Officer Jonathan Mark Hopper reported multiple equity compensation transactions tied to restricted stock units (RSUs). On the transaction date, several RSU awards vested and were converted to common stock, and some RSUs were deferred into phantom stock under Vericel’s Deferred Compensation Plan. The company withheld 1,335 and 636 shares of common stock to satisfy tax obligations at fair market values of
Vericel Corporation’s Principal Accounting Officer, Jonathan Siegal, reported equity award activity involving restricted stock units (RSUs) and common stock. On February 24, 2026, he acquired 1,540 and 1,875 shares of common stock upon vesting of previously granted RSUs.
To cover tax obligations from these vestings, 627 and 738 shares of common stock were withheld by the company at fair market values of
Vericel Corp’s Chief Financial Officer Mara Joseph Anthony Jr reported equity compensation activity rather than open-market trading. On February 24, 2026, restricted stock units vested and were converted into common stock, with blocks of 4,625 shares each delivered. In connection with these vestings, 1,358 shares were withheld in two separate transactions at fair market values of
Vericel Corp Chief Operating Officer Michael Halpin reported equity compensation activity involving Restricted Stock Units (RSUs) and common stock on February 24, 2026. RSU vesting led to multiple exercises (coded “M”), each for 5,250 units or shares at a price of $0.00 per share, increasing his direct holdings in both RSUs and common stock.
The filing shows common shares withheld in two “F”-coded transactions for 2,486 shares each, at fair market values of $38.09 and $38.25 per share, to satisfy tax withholding obligations. After these transactions, Halpin directly held 26,385 shares of Vericel common stock, along with RSU awards that continue to vest annually through February 2029.
Vericel Corp Chief Legal Officer Sean C. Flynn reported equity award activity on February 24, 2026. He acquired 3,500 and 3,000 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs) granted in 2025 and 2024, respectively. A total of 1,553 and 1,331 shares of common stock were withheld by Vericel at fair market values of $38.09 and $38.25 per share to cover tax obligations tied to these vestings. After these transactions, Flynn directly owned 7,683 shares of Vericel common stock.
Vericel Corporation focuses on advanced therapies for sports medicine and severe burn care, built around three marketed products: MACI for knee cartilage repair, Epicel for extensive burns, and NexoBrid for enzymatic removal of burn eschar in adults and children.
The company is expanding MACI through the arthroscopic MACI Arthro technique, now FDA‑approved and launched in 2024, and by targeting more surgeons and indications, including a pivotal ankle trial (MASCOT) and a planned UK launch via the MHRA’s recognition pathway. Its new Burlington, Massachusetts facility is intended to become the primary global manufacturing site for MACI and Epicel.
Vericel also grows its burn franchise by pairing Epicel with NexoBrid, supported by exclusive North American rights from MediWound. As of February 19, 2026, 50,763,319 common shares were outstanding, and the aggregate market value of non‑affiliate shares was about $2.1 billion as of June 30, 2025.
Vericel Corporation reported strong fourth-quarter and full-year 2025 results. Total 2025 revenue rose to $276.3 million, up 16% from 2024, driven by MACI revenue of $239.5 million, which grew 21%. Net income increased to $16.5 million, a 59% gain, and full-year gross margin improved to 74%.
In the fourth quarter, revenue grew 23% to $92.9 million, including $84.1 million from MACI, and gross margin reached a record 79%. The company ended 2025 with approximately $200 million in cash and investments and no debt. For 2026, Vericel projects total revenue of $316–$326 million, MACI revenue of $280–$286 million, gross margin of about 75%, and adjusted EBITDA margin of about 27%.